Roth Capital upgraded shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) from a neutral rating to a buy rating in a research report report published on Friday, Marketbeat.com reports. They currently have $6.00 price target on the stock. The analysts noted that the move was a valuation call.

Separately, Aegis initiated coverage on Tonix Pharmaceuticals Holding Corp. in a report on Monday, June 26th. They issued a buy rating and a $10.00 target price for the company.

Shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ TNXP) opened at 2.95 on Friday. Tonix Pharmaceuticals Holding Corp. has a 52-week low of $2.85 and a 52-week high of $28.00. The company has a 50-day moving average price of $3.87 and a 200-day moving average price of $3.29. The company’s market cap is $22.15 million.

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) last announced its earnings results on Monday, August 14th. The company reported ($0.65) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.78) by $0.13. On average, equities analysts predict that Tonix Pharmaceuticals Holding Corp. will post ($3.16) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/08/21/tonix-pharmaceuticals-holding-corp-tnxp-lifted-to-buy-at-roth-capital.html.

In related news, CEO Seth Lederman bought 20,000 shares of the company’s stock in a transaction dated Thursday, August 17th. The stock was purchased at an average price of $3.00 per share, for a total transaction of $60,000.00. Following the acquisition, the chief executive officer now owns 11,166 shares in the company, valued at $33,498. The purchase was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Ernest Mario sold 6,105 shares of Tonix Pharmaceuticals Holding Corp. stock in a transaction that occurred on Friday, June 30th. The stock was sold at an average price of $4.28, for a total value of $26,129.40. Following the completion of the transaction, the director now owns 63,073 shares of the company’s stock, valued at approximately $269,952.44. The disclosure for this sale can be found here. In the last quarter, insiders bought 50,000 shares of company stock valued at $188,050. Company insiders own 4.00% of the company’s stock.

Several large investors have recently modified their holdings of the company. B. Riley Financial Inc. acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the second quarter worth about $1,637,000. Vanguard Group Inc. raised its stake in shares of Tonix Pharmaceuticals Holding Corp. by 28.8% in the second quarter. Vanguard Group Inc. now owns 184,377 shares of the company’s stock worth $799,000 after buying an additional 41,264 shares in the last quarter. Citadel Advisors LLC acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $119,000. Dialectic Capital Management LP acquired a new stake in shares of Tonix Pharmaceuticals Holding Corp. during the first quarter worth about $187,000. Finally, Renaissance Technologies LLC raised its stake in shares of Tonix Pharmaceuticals Holding Corp. by 108.4% in the fourth quarter. Renaissance Technologies LLC now owns 774,603 shares of the company’s stock worth $364,000 after buying an additional 402,898 shares in the last quarter. 17.50% of the stock is owned by hedge funds and other institutional investors.

Tonix Pharmaceuticals Holding Corp. Company Profile

Tonix Pharmaceuticals Holding Corp., a clinical-stage pharmaceutical company, engages in developing pharmaceutical products for central nervous system disorders. The company’s lead program focuses on post-traumatic stress disorder (PTSD) that is characterized by chronic disability, inadequate treatment options, high utilization of healthcare services, and economic burden.

Receive News & Stock Ratings for Tonix Pharmaceuticals Holding Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tonix Pharmaceuticals Holding Corp. and related stocks with our FREE daily email newsletter.